FDA Clears First Gene Therapy Clinical Trial for Ultra-Rare Pediatric Neurodegenerative Disease MLIV
核心洞察
The FDA has allowed an Investigational New Drug (IND) application to proceed for the first-ever U.S. clinical trial of an experimental gene therapy for Mucolipidosis Type IV (搜索) (MLIV), an ultra-rare inherited neurological disease affecting fewer than 100 known children worldwide.
The investigational therapy uses an AAV9 vector to deliver a functional copy of the MCOLN1 (搜索) gene, aiming to restore production of the deficient mucolipin-1 (搜索) protein that drives the disease.
The milestone culminates nearly a decade of Foundation-coordinated research, including preclinical work at Massachusetts General Hospital and the University of Massachusetts Gene Therapy Center (搜索).
The U.S. Food and Drug Administration (FDA) has allowed an Investigational New Drug (IND) application to proceed for the first-ever U.S. clinical trial of an experimental gene therapy for Mucolipidosis Type IV (搜索) (MLIV), an ultra-rare inherited neurological disease affecting fewer than 100 known children worldwide. The announcement, made by the Mucolipidosis Type IV (ML4) Foundation on September 2, 2026, marks a historic first-in-human milestone for a condition that currently has no approved disease-modifying treatment.
For Randy Gold, President of the ML4 Foundation (搜索), and his wife Caroline, the milestone is deeply personal. Their daughter Eden, now 18, was diagnosed with MLIV as a toddler, inspiring them to help lead the Foundation's effort to develop a treatment. "When Eden was diagnosed, there was no treatment and only early stage research offering families hope," said Gold. "We became involved because we believed science could offer these children a different future, and we were determined to help make that possible. Now there is an investigational drug developed specifically for MLIV that the FDA has permitted to move into human testing. For our family and every family affected by this disease, that is remarkable."
Disease Background and Unmet Need
MLIV is caused by mutations in the MCOLN1 (搜索) gene, resulting in a deficiency of the protein mucolipin-1 (搜索) and severe neurological and developmental impairment. Most children with MLIV never learn to walk or talk, typically function at approximately a 15-month developmental level, experience progressive vision loss, and have shortened lifespans. There is no approved disease-modifying treatment for the condition.
Mechanism of the Investigational Therapy
The investigational treatment is designed to address the underlying genetic cause of MLIV. It uses an adeno-associated virus serotype 9 (AAV9) vector to deliver a functional copy of the gene responsible for producing mucolipin-1 (搜索), with the goal of enabling cells to produce the protein deficient in people with MLIV.
The drug will be administered directly into the brain by a neurosurgeon using a specialized approach designed to reach targeted regions of the central nervous system. Patients will also undergo temporary immune suppression associated with administration of the AAV-based therapy.
Nearly a Decade of Research
Reaching the clinical trial stage required nearly a decade of scientific, manufacturing, and regulatory work coordinated by the ML4 Foundation (搜索). The Foundation invested millions of dollars and assembled a team of researchers, clinicians, gene therapy specialists, manufacturers, regulatory experts, donors, and affected families needed to translate the treatment from the laboratory to children.
Beginning in 2017, the Foundation made gene therapy a major focus. Research at Massachusetts General Hospital, led by Drs. Susan Slaugenhaupt and Yulia Grishchuk, produced findings by Dr. Grishchuk published in 2021 showing the therapy corrected neurological dysfunction in a mouse model. The Foundation and MGH also established an MLIV Natural History Study documenting disease progression.
In 2023, the Foundation engaged Dr. Miguel Sena-Esteves, Dr. Heather Gray-Edwards, and the University of Massachusetts Gene Therapy Center (搜索) to complete preclinical work and translate the therapy into a clinical program. This work included toxicology studies conducted by Charles River Laboratories; production of clinical-grade drug by Andelyn Biosciences (搜索); and extensive stability, sterility, potency, compatibility, and dose-related testing, culminating in the IND authorization.
"Developing a gene therapy for an ultra-rare disease presents an incredible challenge," Gold said. "There was no pharmaceutical company waiting to develop this treatment. Families, researchers, donors and supporters had to build the path ourselves. Together we moved this therapy from an idea in a laboratory to an investigational new drug that will now be studied in children."
Uncertainties and Next Steps
Because the treatment has never been administered to a person with MLIV, researchers do not know whether it will provide clinical benefit, the magnitude or timing of any benefit, whether patients will respond similarly, or what adverse effects or unforeseen consequences may occur.
"This is a moment of tremendous hope, but it is also the beginning of the next scientific chapter," Gold said. "The first children who receive this therapy and the families who make that decision will be doing something extraordinary. We do not yet know what the therapy will do. That is precisely why this trial is so important."
Information about the trial, including eligibility and enrollment, will become available as participating institutions complete the remaining institutional and regulatory steps. The Foundation hopes the first children will be treated in 2026.